Related Experiment Video
Updated: May 19, 2026
The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia
Published on: November 19, 2008
Sodium pyruvate reduces hypoxic-ischemic injury to neonatal rat brain
Rui Pan1, Zhihui Rong, Yun She
1Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Insights
Sodium pyruvate (SP) protects neonatal brains from hypoxic-ischemic (HI) injury by improving metabolism and mitochondrial function. This treatment reduces brain damage and enhances neurological performance in neonatal rats.
Area of Science:
- Neuroscience
- Biochemistry
- Neonatal Medicine
Background:
- Neonatal hypoxia-ischemia (HI) causes severe brain damage, high mortality, and lifelong disability.
- Immature brains are highly vulnerable to HI, leading to mitochondrial neuronal death.
- Sodium pyruvate (SP) is an extracellular antioxidant and potential treatment for hypoxic-ischemic encephalopathy.
Purpose of the Study:
- Evaluate the neuroprotective effects of sodium pyruvate (SP) in neonatal hypoxic-ischemic encephalopathy.
- Assess SP's efficacy in established neonatal rat models of HI.
- Investigate the underlying mechanisms of SP's neuroprotection.
Main Methods:
- Primary cortical neuron cultures from neonatal rats exposed to oxygen and glucose deprivation (OGD).
- A well-established neonatal rat model of hypoxia-ischemia (HI).
- Assessment of brain tissue loss, sensorimotor function, and spatial memory.
Main Results:
- SP significantly reduced brain damage and improved neurological performance in the HI model.
- SP maintained adenosine triphosphate (ATP) levels and prevented reactive oxygen species (ROS) increase.
- SP decreased Bax levels, blocked caspase-3 activation, and activated Akt signaling.
Conclusions:
- Sodium pyruvate (SP) demonstrates significant neuroprotective effects against neonatal HI brain injury.
- SP preserves cerebral metabolism and mitochondrial function during HI.
- SP acts through modulating cell death pathways and activating survival signaling.
Background:
Neonatal hypoxia-ischemia (HI) remains a major cause of severe brain damage and is often associated with high mortality and lifelong disability. Immature brains are extremely sensitive to HI, shown as prolonged mitochondrial neuronal death. Sodium pyruvate (SP), a substrate of the tricarboxylic acid cycle and an extracellular antioxidant, has been considered as a potential treatment for hypoxic-ischemic encephalopathy, but its effects have not been evaluated in appropriate animal models for hypoxic-ischemic encephalopathy.
Methods:
This investigation used primary cortical neuron cultures derived from neonatal rats subjected to oxygen and glucose deprivation (OGD) and a well-established neonatal rat HI model.
Results:
HI caused brain tissue loss and impaired sensorimotor function and spatial memory whereas SP significantly reduced brain damage and improved neurological performance. These neuroprotective effects of SP are likely the result of improved cerebral metabolism as demonstrated by maintaining adenosine triphosphate (ATP) levels and preventing an increase in intracellular reactive oxygen species (ROS) levels. SP treatment also decreased levels of Bax, a death signal for immature neurons, blocked caspase-3 activation, and activated a key survival signaling kinase, Akt, both in vitro and in vivo.
Conclusion:
SP protected neonatal brain from hypoxic-ischemic injury through maintaining cerebral metabolism and mitochondrial function.
